(Q38548750)

English

Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials.

scientific article published on 17 July 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26183252%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

0 references

1 reference

Europe PubMed Central

Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26183252%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

1 reference

based on heuristic

inferred from title

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Jonathan Golledge

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26183252%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26183252%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

author name string

A Sahebkar

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26183252%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

L E Simental-Mendía

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26183252%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

F Guerrero-Romero

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26183252%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

publication date

14 September 2015

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26183252%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26183252%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26183252%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26183252%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

1042-1055

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26183252%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12536

21 January 2018

Structural mechanism for statin inhibition of HMG-CoA reductase

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12536

21 January 2018

PCSK9 inhibition: the next statin?

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12536

21 January 2018

The biology and therapeutic targeting of the proprotein convertases

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12536

21 January 2018

Recent advances in pharmacotherapy for hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12536

21 January 2018

New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12536

21 January 2018

New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect?

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12536

21 January 2018

Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12536

21 January 2018

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12536

21 January 2018

Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12536

21 January 2018

Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12536

21 January 2018

Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12536

21 January 2018

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12536

21 January 2018

Estimating the mean and variance from the median, range, and the size of a sample

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12536

21 January 2018

Does PPARγ2 gene Pro12Ala polymorphism affect nonalcoholic fatty liver disease risk? Evidence from a meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12536

21 January 2018

Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12536

21 January 2018

Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12536

21 January 2018

Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12536

21 January 2018

Plasma PCSK9 levels are significantly modified by statins and fibrates in humans

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12536

21 January 2018

Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12536

21 January 2018

Short-term impact of low-dose atorvastatin on serum proprotein convertase subtilisin/kexin type 9.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12536

21 January 2018

Policosanol attenuates statin-induced increases in serum proprotein convertase subtilisin/kexin type 9 when combined with atorvastatin

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12536

21 January 2018

Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12536

21 January 2018

Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12536

21 January 2018

Efficacy and safety of coadministration of rosuvastatin, ezetimibe, and colestimide in heterozygous familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12536

21 January 2018

Ancestry and other genetic associations with plasma PCSK9 response to simvastatin

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12536

21 January 2018

Evidence from a randomized trial that simvastatin, but not ezetimibe, upregulates circulating PCSK9 levels

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12536

21 January 2018

Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12536

21 January 2018

High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12536

21 January 2018

A new method for measurement of total plasma PCSK9: clinical applications

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12536

21 January 2018

On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12536

21 January 2018

Receptor-mediated endocytosis: concepts emerging from the LDL receptor system

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12536

21 January 2018

Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12536

21 January 2018

The combination of Ezetimibe and Statin: a new treatment for hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12536

21 January 2018

Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12536

21 January 2018

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12536

21 January 2018

PCSK9 antibodies for the treatment of hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12536

21 January 2018

Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12536

21 January 2018

Dual regulation of the LDL receptor--some clarity and new questions

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12536

21 January 2018

Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12536

21 January 2018

Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. Effect of patient characteristics on lovastatin-induced changes in plasma concentrations of lipids and lipoproteins

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12536

21 January 2018

Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12536

21 January 2018

PCSK9 as a therapeutic target of dyslipidemia

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12536

21 January 2018

Identifiers

10.1111/DOM.12536

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26183252%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26183252%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38548750&oldid=2109613071"